Certolizumab Pegol in Combination with Methotrexate in DMARD-Naive Patients with Active, Severe, Progressive Rheumatoid Arthritis: Results from a Randomized, Double-Blind, Controlled Phase 3 Study

被引：0

作者：

Weinblatt, Michael ^{[1
]}

Bingham, Clifton ^{[2
]}

Burmester, Gerd ^{[3
]}

Bykerk, V. P. ^{[4
]}

Furst, Daniel E. ^{[5
]}

Mariette, Xavier ^{[6
]}

van der Heijde, Desiree ^{[7
]}

Tatla, Daljit ^{[8
]}

Arendt, Catherine ^{[9
]}

Mountian, Irina ^{[10
]}

VanLunen, Brenda ^{[11
]}

Emery, Paul ^{[12
]}

机构：

[1] Brigham & Womens Hosp, Rheumatol Immunol & Allergy, Boston, MA 02115 USA

[2] Johns Hopkins Univ, Baltimore, MD USA

[3] Charite, Dept Rheumatol & Clin Immunol, D-13353 Berlin, Germany

[4] Hosp Special Surg, Rheumatol, New York, NY 10021 USA

[5] Univ Calif Los Angeles, David Geffen Sch Med, Med, Los Angeles, CA 90095 USA

[6] Univ Paris 11, Hop Univ Paris Sud, AP HP, Paris, France

[7] State Univ Limburg Hosp, NL-6201 BX Maastricht, Netherlands

[8] UCB Pharma, Raleigh, NC USA

[9] UCB Pharma, Global Med Affairs, Brussels, Belgium

[10] UCB Pharma, Brussels, Belgium

[11] UCB Pharma, Raleigh, NC USA

[12] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England

来源：

ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

968

引用

页数：3

共 50 条

[1] IMPROVEMENTS IN WORKPLACE AND HOUSEHOLD PRODUCTIVITY FOLLOWING 52 WEEKS OF TREATMENT WITH CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE IN DMARD-NAIVE PATIENTS WITH SEVERE, ACTIVE AND PROGRESSIVE RHEUMATOID ARTHRITIS: RESULTS FROM THE C -EARLY RANDOMIZED, DOUBLE-BLIND, CONTROLLED PHASE 3 STUDY
Emery, P.
Bingham, C.
Burmester, G. R.
Bykerk, V. P.
Furst, D.
Mariette, X.
Purcaru, O.
VanLunen, B.
Weinblatt, M.
[J]. VALUE IN HEALTH, 2015, 18 (07) : A710 - A710
[2] IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES FOLLOWING 52 WEEKS OF TREATMENT WITH CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE IN DMARD-NAIVE PATIENTS WITH SEVERE, ACTIVE AND PROGRESSIVE RHEUMATOID ARTHRITIS: RESULTS FROM THE C-EARLY RANDOMIZED, DOUBLE-BLIND, CONTROLLED PHASE 3 STUDY
Emery, P.
Bingham, C.
Burmester, G.
Bykerk, V
Furst, D.
Mariette, X.
Purcaru, O.
Coteur, G.
Vanlunen, B.
Weinblatt, M.
[J]. VALUE IN HEALTH, 2015, 18 (07) : A707 - A708
[3] Early Response As a Predictor of Long-Term Remission in DMARD-Naive Patients with Severe, Active and Progressive Rheumatoid Arthritis Treated with Certolizumab Pegol in Combination with Methotrexate
Weinblatt, Michael
Bingham, Clifton
Burmester, Gerd
Bykerk, V. P.
Furst, Daniel E.
Mariette, Xavier
van der Heijde, Desiree
Tatla, Daljit
Arendt, Catherine
Mountian, Irina
VanLunen, Brenda
Emery, Paul
[J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
[4] THE FIRST STUDY OF CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE IN DMARD-NAIVE EARLY RHEUMATOID ARTHRITIS PATIENTS LED TO SUSTAINED CLINICAL RESPONSE AND INHIBITION OF RADIOGRAPHIC PROGRESSION AT 52 WEEKS: THE C-EARLY RANDOMIZED, DOUBLE-BLIND, CONTROLLED PHASE 3 STUDY
Emery, P.
Bingham, C. O.
Burmester, G. -R.
Bykerk, V. P.
Furst, D. E.
Mariette, X.
van der Heijde, D.
Tatla, D.
Arendt, C.
Mountian, I.
VanLunen, B.
Weinblatt, M.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 712 - 712
[5] Reduction of Disease Burden on Workplace and Household Productivity Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in DMARD-Naive Patients with Active, Severe, Progressive Rheumatoid Arthritis
Bykerk, V. P.
Bingham, Clifton
Burmester, Gerd
Furst, Daniel E.
Mariette, Xavier
Purcaru, Oana
VanLunen, Brenda
Weinblatt, Michael
Emery, Paul
[J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
[6] IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AND WORKPLACE AND HOUSEHOLD PRODUCTIVITY FOLLOWING 52 WEEKS OF TREATMENT WITH CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE IN DMARD-NAIVE EARLY RHEUMATOID ARTHRITIS PATIENTS: RESULTS FROM THE C-EARLY RANDOMIZED, DOUBLE-BLIND, CONTROLLED PHASE 3 STUDY
Emery, P.
Bingham, C. O.
Burmester, G. -R.
Bykerk, V. P.
Furst, D. E.
Mariette, X.
Purcaru, O.
Coteur, G.
VanLunen, B.
Weinblatt, M.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 712 - 713
[7] Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
Emery, P.
Bingham, C. O., III
Burmester, G. R.
Bykerk, V. P.
Furst, D. E.
Mariette, X.
van der Heijde, D.
van Vollenhoven, R.
Arendt, C.
Mountian, I.
Purcaru, O.
Tatla, D.
VanLunen, B.
Weinblatt, M. E.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (01) : 96 - 104
[8] Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study
Bi, L.
Li, Y.
He, L.
Xu, H.
Jiang, Z.
Wang, Y.
Li, X.
Wei, W.
Gu, J.
Wang, G.
Zhang, Z.
Zhou, B.
Liu, Y.
Wu, Z.
Liu, H.
He, D.
Lv, Z.
Li, Z.
Zuo, X.
Dong, L.
Wu, H.
Zhang, H.
Chen, H.
Bao, C.
Zhang, Z.
Zhang, M.
Song, H.
Zheng, Y.
Jiang, L.
Liu, X.
Boehnlein, M.
Dunkel, J.
Shao, J.
Harris, K.
Li, Z.
[J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (02) : 227 - 234
[9] A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study Evaluating Treatment Strategies (Continuation Versus Withdrawal) for Maintaining Low Disease Activity after 1 Year of Certolizumab Pegol in DMARD-Naive Patients with Early and Progressive, Active RA
Weinblatt, Michael
Bingham, Clifton, III
Burmester, Gerd-Ruediger
Bykerk, Vivian P.
Furst, Daniel E.
Mariette, Xavier
van der Heijde, Desiree
van Vollenhoven, Ronald
VanLunen, Brenda
Ecoffet, Cecile
Cioffi, Christopher
Emery, Paul
[J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
[10] Rapid Onset of Response Observed with Certolizumab Pegol in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Efficacy and Safety Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study
Bi, Liqi
Li, Yuhui
He, Lan
Xu, Huji
Gu, Jieruo
Wang, Guochun
Zhang, Zhiyi
Liu, Yi
Boehnlein, Marion
Dunkel, Jochen
Shao, Jing
Harris, Kristina
Li, Zhanguo
[J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69

← 1 2 3 4 5 →